Insider · CIK 0001353128

DUNCAN BARBARA GAYLE

Reports to the SEC for 11 companies · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001353128

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-18	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−29.6K sh	—	—	0
2026-06-18	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director	AAward	+26.7K sh	—	—	26,700
2026-06-18	AVIRAtea Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+29.6K sh	—	—	92,350
2026-06-18	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+37.7K sh	—	—	37,700
2026-05-05	HALOHALOZYME THERAPEUTICS, INC. · Option to Purchase Common StockA Award	Director	AAward	+6,040 sh	—	—	6,040
2026-05-05	HALOHALOZYME THERAPEUTICS, INC.A Award	Director	AAward	+3,796 sh	—	—	23,715
2026-02-26	OVIDOvid Therapeutics Inc. · Employee Stock Option (Right to Buy)A Award	Director	AAward	+65K sh	—	—	65,000
2025-06-20	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−29.6K sh	—	—	0
2025-06-20	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+41.2K sh	—	—	41,200
2025-06-20	AVIRAtea Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+29.6K sh	—	—	62,750
2025-06-20	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director	AAward	+29.6K sh	—	—	29,600
2025-05-01	HALOHALOZYME THERAPEUTICS, INC.A Award	Director	AAward	+4,165 sh	—	—	19,919
2025-05-01	HALOHALOZYME THERAPEUTICS, INC. · Option to Purchase Common StockA Award	Director	AAward	+5,750 sh	—	—	5,750
2025-02-20	OVIDOvid Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+45K sh	—	—	45,000
2024-12-12	OVIDOvid Therapeutics Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+90K sh	—	—	90,000
2024-06-21	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director	AAward	+29.6K sh	—	—	29,600
2024-06-21	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+41.2K sh	—	—	41,200
2024-06-16	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−33.2K sh	—	—	0
2024-06-16	AVIRAtea Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+33.2K sh	—	—	33,150
2024-06-04	Fusion Pharmaceuticals Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17K sh	—	—	0
2024-06-04	Fusion Pharmaceuticals Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17K sh	—	—	0
2024-06-04	Fusion Pharmaceuticals Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17K sh	—	—	0
2024-06-04	Fusion Pharmaceuticals Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−30K sh	—	—	0
2024-04-25	HALOHALOZYME THERAPEUTICS, INC. · Option to Purchase Common StockA Award	Director	AAward	+8,804 sh	—	—	8,804
2024-04-25	HALOHALOZYME THERAPEUTICS, INC.A Award	Director	AAward	+6,501 sh	—	—	15,754
2024-02-22	OVIDOvid Therapeutics Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2023-06-16	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director	AAward	+33.2K sh	—	—	33,150
2023-06-16	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+46.8K sh	—	—	46,750
2023-06-14	Fusion Pharmaceuticals Inc.Stock Opion (Right to Buy)A Award	Director	AAward	+17K sh	—	—	17,000
2023-05-05	HALOHALOZYME THERAPEUTICS, INC.A Award	Director	AAward	+8,065 sh	—	—	9,253
2023-05-05	HALOHALOZYME THERAPEUTICS, INC. · Option to Purchase Common StockA Award	Director	AAward	+11.4K sh	—	—	11,371
2023-05-03	Jounce Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15.7K sh	—	—	0
2023-05-03	Jounce Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−13.6K sh	—	—	0
2023-05-03	Jounce Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10.8K sh	—	—	0
2023-05-03	Jounce Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−34.3K sh	—	—	0
2023-05-03	Jounce Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20K sh	—	—	0
2023-05-03	Jounce Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15.7K sh	—	—	0
2023-05-03	Jounce Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15.7K sh	—	—	0
2023-02-23	OVIDOvid Therapeutics Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2023-02-03	HALOHALOZYME THERAPEUTICS, INC.A Award	Director	AAward	+1,188 sh	—	—	1,188
2022-07-01	ADAPAdaptimmune Therapeutics PLC · Option to purchase Ordinary SharesA Award	Director	AAward	+500K sh	—	—	500,000
2022-06-24	Jounce Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2022-06-17	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+61.3K sh	—	—	61,264
2022-06-14	Fusion Pharmaceuticals Inc.Stock Opion (Right to Buy)A Award	Director	AAward	+17K sh	—	—	17,000
2022-04-08	OVIDOvid Therapeutics Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+21.3K sh	—	—	21,347
2022-02-03	OVIDOvid Therapeutics Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2021-07-01	ADAPAdaptimmune Therapeutics PLC · Option to purchase Ordinary SharesA Award	Director	AAward	+380K sh	—	—	379,788
2021-06-18	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+34K sh	—	—	34,025
2021-06-18	Jounce Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+15.7K sh	—	—	15,700
2021-06-11	OVIDOvid Therapeutics Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000

Recent filings

Accepted (ET)
Jun 234
DUNCAN BARBARA GAYLE0001193125-26-279721
SEC(opens sec.gov)
May 74
DUNCAN BARBARA GAYLE0001159036-26-000060
SEC(opens sec.gov)
Mar 24
DUNCAN BARBARA GAYLE0001353128-26-000002
SEC(opens sec.gov)
Jun 244
Duncan Barbara Gayle0000950170-25-089609
SEC(opens sec.gov)
Jun 184
Duncan Barbara Gayle0001415889-25-017696
SEC(opens sec.gov)
May 24
Duncan Barbara Gayle0001415889-25-011769
SEC(opens sec.gov)
Dec 164
Duncan Barbara Gayle0001415889-24-029472
SEC(opens sec.gov)
Jun 214
Duncan Barbara Gayle0000950170-24-076400
SEC(opens sec.gov)
Jun 184
Duncan Barbara Gayle0000950170-24-074985
SEC(opens sec.gov)
Jun 44
Duncan Barbara Gayle0000950170-24-068885
SEC(opens sec.gov)

Companies

Address

225 FRANKLIN STREET SUITE 2100

BOSTON, MA, 02110